Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment.

ABSTRACT:

Background

The direct oral anticoagulants (DOACs), apixaban and rivaroxaban, have been studied for extended-phase treatment of venous thromboembolism (VTE). Yet, scant evidence exists surrounding clinician practice and decision-making regarding dose reduction.

Aims

Report clinician practice and characteristics surrounding dose reduction of DOACs for extended-phase VTE treatment.

Methods

We conducted a 16-question REDCap survey between July 14, 2021, and September 13, 2021, among ISTH 2021 Congress attendees and on Twitter. We explored factors associated with dose reduction using logistic regression. We used k-means clustering to identify distinct groups of dose-reduction decision-making. Random forest analysis explored demographics with respect to identified groups.

SUBMITTER: Groat D 

PROVIDER: S-EPMC9175245 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature